The size of the Europe Non-Insulin Diabetes Therapies market has been estimated at USD 2.4 million in 2020 and is expected to grow at a CAGR of 4.77% to reach USD 3.03 million by 2025.
Non-Insulin Diabetes occurs due to metabolic disorders and the main symptoms are high levels of sugar in blood, low levels of insulin. The main reasons for the up growth of this market are: food habits, increasing urbanisation resulting in cultural changes rapidly, different lifestyles. These are the factors resulting the growth of Type-2 Non-Insulin Diabetes Therapies.
The market is segmented mainly by drug type. By drug type market is categorised by Sulphonylureas, Amylin Agonists, GLP-1 Agonists & Analogs , Biguanides , Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors , Alpha-Glucosidase Inhibitors , Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Thiazolidinediones (or Glitazones or TZDs), Glinides or Meglitinides .Non-Insulin Diabetes Medication market is anticipated to experience a higher CAGR in coming days, because of the increase in the percentage of people affected by Type-2 Diabetes. Several companies and Industries have been working to find the appropriate medication without causing any side effects. Nowadays pharma companies are trying to adopt methods and produce drugs which when injected into the body enables liver to produce Insulin. These are called non-Insulin Diabetes Medication. Non-Insulin Diabetic therapies are mostly oral based therapies; this is prescribed prior to using insulin in the line of therapy. Till 2016 most of the medications available for Diabetes are Insulin based and recent research shows us by 2023 more than 40% of the medications available in the market will be non- insulin products.
By geography the market is segmented into UK, Spain, Germany, France and others. Recent analysis show us, in Germany around 5 million people are facing diabetic problems. Because of growth in number of people facing diabetic problems, the growth in this market is expected to increase exponentially in coming years.
Promising companies treating Diabetes in the market include Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), Astrazeneca (U.K), Boehringer Ingelheim (Germany), Bayer (Germany).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 Sulphonylureas
5.1.3 Amylin Agonists
5.1.4 GLP-1 Agonists & Analogs
5.1.5 Biguanides
5.1.6 Glinides & Meglinitides
5.1.7 Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
5.1.8 Thiazolidinediones (or Glitazones or TZDs
5.1.9 Alpha-Glucosidase Inhibitors
5.1.10 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
5.1.11 Y-o-Y Growth Analysis, By Drug Type
5.1.12 Market Attractiveness Analysis, By Drug Type
5.1.13 Market Share Analysis, By Drug Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Product
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Tobira
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novo Nordisk
8.3 Takeda and Sanofi
8.4 Eli Lilly Sumitomo Dainippon Pharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
